initi coverag
long paw bag initi ow pt
invest summari initi coverag
overweight rate price target believ pipelin
novel anim health drug drive long-term sharehold valu advanc
pipelin think investor begin appreci peak revenu potenti
product compani bring market kindr one approv product
mirataz expect approv zimeta iv later year two approv
year thereaft expect upward earn revis multipl expans
pipelin advanc drive stock higher
 mirataz could game changer cat owner kindr first product
approv earlier year transderm ointment treat inappet
cat given difficulti pill cat cat treat
unintend weight loss year believ mirataz could gener revenu
well-abov street current forecast kindr price mirataz
reason view drive uptak product
stand-alone treatment inappet well co-prescrib medic
believ kindr proprietari transderm accusorb technolog could appli
futur product
felin erythropoietin antibodi target larg market opportun
includ canin atop dermat given durabl natur anim health
product current anim health biosimilar pathway kindr
success bring biolog market could gener signific
long-term cash flow peak sale approach
refer sale estim model could
conserv kindr success bring pipelin market
 uniqu asset anim health rare demand premium kindr
small molecul platform altern dose technolog biolog pipelin
make uniqu anim health compani histor seen larger
anim health compani ow cover louis chen elanco
part ow cover louis chen will spend
multipl high sale acquir uniqu asset believ
willing pay premium asset due overal durabl
anim health revenu scarciti asset anim health
space larg anim health compani separ stand-alone entiti
expect competit premium asset may increas
 valuat use blend dcf ev/ebitda arriv pt
disclosur section may found page
companion anim health compani focus bring small molecul
monoclon antibodi product market kindr target therapi within canin felin equin
companion anim market kindr approach drug develop target molecul known
work human repurpos molecul appli pet reduc technic risk
time involv drug develop compani first product approv year mirataz
expect second approv end year two approv per year thereaft
expect kindr pipelin advanc drive appreci valu kindr potenti
product could unlock expect product approv drive upsid earn estim level
current reflect stock pleas see perform outlook section
detail forecast compani
support reason kindr stock
kindr uniqu asset anim health segment large-cap compani spin
anim health asset think stand-alone compani increasingli look add differenti
asset portfolio given kindr portfolio asset potenti bring market-lead
biolog antibodi market target larg opportun atop dermat believ
kindr asset would highli valu larger acquir signific anim health
asset acquir last year zoetiss ow cover louis chen acquisit
pharmaq elanco acquisit boehring ingelheim vetmedica felin
canin rabi vaccin portfolio zoetiss acquisit abaxi
asset acquir sale kindr price target assum ev/sal multipl
revenu estim
exhibit kindr pt valuat compar select anim health acquisit
small molecul platform could help cat gain weight kindr receiv approv first product
earlier year mirataz believ mirataz potenti gener peak sale
direct sale forc peopl compani abl achiev peak sale estim
provid signific leverag busi model result signific ebitda cash
flow gener reinvest compani antibodi pipelin addit mirataz
yearbuy namesel nameev mm ev /salesev boehring ingelheim vetmedica felin canin rabi vaccin bioscinec base ev per price target dcf cantor fitzgerald cantor fitzgerald research factset compani report ev mean enterpris valu multipl calcul histor sale ebitda except kindr base ev/saleskindr bioscienc inc class anim health corpor class juli
kindr expect gain approv year zimeta treatment control pyrexia fever
hors kindr expect first receiv approv iv form zimeta later oral gel
version given size equin market kindr expect commerci equin product
small sale forc expect kindr reinvest meaning portion small
molecul cash flow gener develop pipelin kindr expect receiv two
approv two year thereaft furthermor believ kindr proprietari
transderm accusorb technolog could appli addit undisclos product futur
small molecul platform scratch surfac kindr biolog platform
potenti one lead anim health biolog platform view given manag
expertis develop human health biolog indic target compani
method leverag expertis develop anim health product recent
valid zoetiss partnership regeneron cover kindr antibodi pipelin
target indic potenti grow larg market opportun compani
includ atop dermat zoetiss apoquel cytopoint treat dermatolog problem
dog atop dermat expect gener peak sale zoeti note
continu see strong growth cytopoint outsid most-rec
report quarter report combin revenu two product
gener cytopoint cytopoint current cost per inject
depend size dog use chronic everi four-six week given larg number
dog high preval atop dermat believ kindr
zoeti success market kindr product pipelin current consist disclos
product addit undisclos candid pipelin includ kind-bodi ige antibodi
antibodi vegf antibodi checkpoint inhibitor product
anim cash flow durabl sustain averag lifespan anim health drug
tend longer human drug thu cash flow durabl better
price power lower gener competit human health drug third-
parti payer forc switch gener anim health market gener self-pay market
therefor larg insur manag formulari enforc gener use instanc
lifespan zoetiss top product year mani anim health product reach peak sale
number year patent expir furthermor gener dispens rate companion anim
health drug remain gener companiesand automat substitut
given mani drug receiv directli vet consid current pathway
gain approv biosimilar product kindr biolog product expect life span
kindr revenu line success anim health product furthermor
anim health spend remain robust veterinari care spend grown
forecast continu grow pace american pet product
associ dont expect trend slow given millenni increasingli human
pet treat would human famili member
spend across categori med veterinari live anim salesoth supplies/otc medic spend med veterinari exhibit detail potenti stock-mov catalyst compani event next import catalyst
mirataz uptak zimeta approv epocat data anti-tnf data
exhibit catalyst event calendar
datedriverupcom ivpreapprov spection pai contract manufacturerbi year end oralsubmit ivapprovalend antibodypilot efficaci resultsearli efficaci resultsearli efficaci approvalstwo product approv per pivot dermat antibodybegin pivot dermat cantor fitzgerald research compani report juli
revenu ep estim exceed street expect due
perceiv lack appreci potenti kindr pipelin street combin
limit publish estim year kindr could gain approv biolog
epocat well first atop dermat antibodi product product
potenti success drive earn beyond street expect current estim
creat meaning long-term sharehold valu given kindr focu sole companion anim
drug believ compani may abl achiev oper margin higher
larger anim health compani diversifi busi includ lower-margin
livestock busi dairi
compani present factset cantor fitzgerald research
price target base dcf ev/ebitda valuat current trade
revenu estim expect kindr bring first antibodi product market
subsequ product come market thereaft given kindr pipelin potenti launch
durabl anim health revenu combin lack
biosimilar pathway model termin growth rate kindr base dcf
analysi believ valuat rang stock includ
busi develop take-out premium analysi acquir would
expect take-out valu per share given manag indic
poison-pil defens place take-out valu per share
ep estim compar consensuscantor fitzgeraldfactset revenu estim compar consensu mm cantor fitzgeraldfactset multipl juli
commercial-stag biopharmaceut compani
compani histori overview
focus develop
commerci novel product aim toward pet kindr strategi identifi compound
target alreadi demonstr safeti efficaci human develop therapeut base
valid compound target pet primarili dog cat hors use
approach kindr expect higher approv success rate shorter develop timelin compar
pursu new non-valid compound target kindr pipelin consist small molecul
biolog rang indic dog cat hors near-term focu equin
small molecul product canin felin biolog product kindr expect two product
approv year averag two approv per year thereaft
incorpor delawar septemb compani head offic locat
decemb compani complet initi public offer list nasdaq
ticker
march compani rais net proce secondari offer
share
august compani announc top-lin pivot result one lead
program cerekin dog osteoarthr meet primari endpoint
decemb kindr made decis stop develop atokin histamin
antagonist treatment atop dermat
march compani announc posit pilot field studi result
control fever hors posit pivot studi result announc later year
januari kindr announc posit result pilot studi
mirataz posit pivot result releas may
may compani announc posit top-lin result pivot pk studi
mirataz known time
may kindr announc compani initi enrol pivot
effect trial zimeta oral posit result releas decemb
june kindr stock ad russel index
juli compani rais gross proce equiti offer
april kindr receiv respons fda chemistri
manufactur control technic section zimeta iv control fever hors
note fda addit question request regard submiss
decemb kindr submit mirataz approv eu
may kindr receiv approv fda compani first product
may compani announc posit result pilot effect studi
treatment gastric ulcer hors
june compani rais gross proce equiti offer
kindr current pipelin focus small molecul well biolog product dog cat
hors near-term focu felin equin small molecul product well canin
felin biolog kindr one approv product mirataz compani expect anoth
potenti approv year zimeta iv treat fever hors kindr expect averag two
product approv year go forward larg market potenti product compani
pipelin target indic compani variou product candid
kindr expect commerci product sale forc well
distributor relationship outsid expect compani seek partnership
kindr direct sale forc companion anim rep equin rep
distribut agreement first kindr sign mwi veterinari suppli co direct
vet market inc vet first choic decemb
kindr small molecul develop program focu identifi compound
demonstr efficaci target popul identifi human drug address
biolog target pathway anim drug kindr work molecul custom
dosag formul flavor characterist product initi pivot trial
kindr abl gain first approv activ ingredi previous approv anim
use compani five year exclus year eu
kindr biolog platform capabl develop biolog includ antibodi fulli
mostli canin felin equin kindr develop long-act felin recombin
erythropoietin antibodi target canin ige tnf
valid target kindr biolog manufactur plant burlingam
california well second facil elwood kansa
mirataz mirtazapin transderm ointment transderm drug approv manag
weight loss cat use kindr proprietari accusorb transderm technolog result
high predict absorpt cat mirtazapin noradrenerg specif serotonerg
antidepress increas level serotonin brain balanc activ serotonin
gastrointestin tract result allevi nausea appetit loss weight loss often first
indic chronic diseas cat exampl cat kidney gastrointestin dental diseas
often exhibit weight loss ill mirataz formerli known top-lin result
announc may drug approv fda may kindr submit
european market author applic mirataz decemb kindr launch
mirataz juli howev expect compani begin book revenu reorder
custom includ mirataz revenu begin although revenu
may begin book
pivot field studi mirataz multi-cent random double-blind placebo-control
studi enrol cat assess effect mirataz manag weight loss cat
primari endpoint percentag chang bodi weight day week week mean
percentag increas bodi weight day group vs
placebo group target anim safeti studi mirataz gener well-
toler signific safeti concern identifi propos label dose topic
administr mirtazapin ointment associ mild revers skin chang site
dose applic ear note howev drug appear well-toler
compani believ abl
activ ingredi mirataz mirtazapin kindr obtain mirtazapin singl
supplier
provid suffici quantiti
commerci compani enter agreement dpt laboratori manufactur
initi launch futur commerci batch mirataz kindr believ dpt capabl
meet excess demand aris
exhibit visual challeng pill
often respond ill eat may perpetu neg outcom cat
cat eat may recov quickli weight loss lead caus visit vet cat
owner vet see seven cat week averag inappet left untreat
inappet life-threaten condit due hepat failur current limit
option vet control weight loss cat normal involv use mirtazapin pill
mirataz first fda-approv transderm medic control weight loss
cat accord compani veterinarian use mirtazapin activ ingredi mirataz
major say would switch transderm mirtazapin gel formul wherea
said would replac mirtazapin would replac mirtazapin
forty-nin percent veterinarian report eas administ medic primari factor
select medic control felin weight loss
panel held earlier year fetch confer ask pet owner would rather
purchas one inject higher cost pill one pet two week panelist agre
would pay higher cost inject rather pay lower cost pill anim
believ sentiment extend willing pay transderm mirataz
market modelnumb inappet cat number cat treat mirataz per label chronic rx per chronic label usag market usag market target market market share mirataz cantor fitzgerald research compani reportsfisc year end decemb juli
veterinarian current use mirtazapin treat inappet cat mirtazapin anti-depress
use human possess appetite-stimul properti veterinarian often give cat
dose oral stimul appetit compar mirataz dose
per day transderm accord greater number advers event occur
cat administ dose cat administ dose studi aspca
show accident ingest excess mirtazapin issu addit eas use
dose cat transderm believ kindr mirataz remov risk over-dos
accident ingest excess mirtazapin therebi reduc advers event associ
also transderm formul mirtazapin compound bulk drug substanc
avail mani compound pharmaci expect veterinarian use mirataz
compound option given veterinarian may make money mirataz cost
pet owner rel similar given kindr conserv price drug
mirataz offer veterinarian approv mirtazapin product known safeti efficaci
qualiti provid patient rather reli unapprov product
compound bulk drug substanc
zimeta previous iv oral drug intend control pyrexia fever
hors zimeta pyrazolon anti-inflammatori drug mechan action differ
tradit nsaid activ ingredi zimeta use hors human
antipyret outsid consid anti-spasmod use hors
without mask surgic sign colic human activ ingredi zimeta rais
concern bone marrow suppress rare case led withdraw drug
certain market howev product continu avail market prescript
counter rare side effect seen hors product wide use
outsid equin veterinarian kindr expect gain approv zimeta iv
potenti approv oral zimeta
kindr announc posit result zimeta iv multi-cent random blind placebo-
control pivot studi enrol hors assess effect zimeta primari
endpoint improv greater decreas temperatur baselin resolut
fever return normothermia hour six follow treatment success rate
group vs placebo group drug appear
well-toler kindr file nada zimeta iv approv expect later year
kindr announc posit top-lin result zimeta oral gel decemb studi
multi-cent random blind placebo-control pivot studi enrol hors assess
effect zimeta oral primari endpoint improv resolut
fever six hour treatment accord compani zimeta oral group achiev
success outcom compar placebo group drug well-
million hors approxim hors treat
fever annual kindr done preliminari market research equin veterinarian
respond believ zimeta good fit practic said would use
zimeta first year model zimeta reach peak sale given small
sale forc requir promot equin product peopl zimeta accret
compani ebitda line soon post launch kindr plan use contract manufactur
manufactur zimeta compani believ manufactur capabl meet excess
demand kindr expect oral gel formul zimeta larger product
complementari iv zimeta without cannib sale iv
market modelnumb hors number hors treat fever annual zimmeta target market market share hors treat zimeta year end decemb juli
kindr biolog platform potenti truli differenti compani small-to-mid-
size anim heath peer view kindr target first bioligc product epocat
recombin long-act felin erythropoietin non-regen anemia cat market
around thereaft expect approv compani first antibodi target canin
atop dermat given compani recent financ believ kindr well-
capit fund biolog platform outsid reli sole revenu gener
mirataz zimeta
kindr industry-lead biolog program aim bring one-of-a-kind product market
companion anim companion anim market significantli smaller human
market develop cost anim health therapeut meaning cheaper
timelin market faster human drug develop kindr experienc team
signific experi knowledg bring human biolog market compani
leverag expertis creat innov therapi aim companion anim kindr
state-of-the-art biolog manufactur plant california abl manufactur epocat
small molecul drug clinic trial batch recent acquir facil kansa
manufactur commercial-stag quantiti atop dermat program
addit kindr epocat antibodi program compani develop scaffold
technolog kind-bodi non-antibodi properti kindr believ make
superior antibodi kindr believ kind-bodi potenti bispecif
abil bind two differ target time compani also think
infring antibodi patent target enabl compani pursu molecul
may superior tradit antibodi well pursu high-valu target antibodi
patent expir key focu area kindr biolog pipelin beyond
antibodi includ new biolog target canin counterpart
human target xolair omalizumab allerg immune-medi diseas asthma
chronic idiourticaria antibodi target activated-glycosyl
phosphoprotein sever antibodi target cytokin involv atop dermat
antibodi target canin tumor necrosi factor tnf
epocat long-act felin recombin erythropoietin design manag non-regen
anemia cat anemia common condit cat half elderli cat develop kidney
diseas caus anemia result decreas level endogen erythropoietin epocat
success complet lab studi show increas reticulocyt formul
deem posit efficaci signal move forward studi epocat current pilot
field efficaci studi expect read-out earli
epocat engin prolong half-lif compar endogen felin
erythropoietin approv veterinari drug manag anemia cat current
non-approv erythropoietin product requir multipl dose week contrast initi data
suggest epocat half-lif may long enough allow singl monthli dose
note epocat pilot field studi goal collect data find optim dose
would suffici increas red blood cell develop cat chronic kidney diseas ckd
cat studi receiv laboratori physic test owner complet survey
week discuss effect epocat data pilot studi expect earli
determin necessari adjust requir epocat formul and/or dose
move forward pivot studi expect begin late
depend pace enrol trial epocat could gain approv
includ model epocat revenu expect first year launch
anemia diseas caus reduc volum red blood cell suppli blood tissu
cat face larg reduct red blood cell bodi requir produc non-
regen anemia bone marrow abl respond produc suffici amount red
blood cell hormon call erythropoietin instruct bone marrow respond produc
major erythropoietin cat come kidney cat face kidney
failur often lead anemia
chronic kidney diseas ckd lead caus anemia cat high preval
ckd found cat older year age elderli cat show symptom increas
breath heartrat lethargi decreas appetit pale gum
accord appa nation pet owner survey cat
household cat estim older cat ckd
translat total cat popul
kindr biolog team high level expertis engin develop
erythropoietin biolog expect compani leverag order bring epocat market
without current commerci approv drug treat anemia cat high unmet need
provid kindr opportun first approv drug market space
 monoclon antibodi canin atop dermat
kindr develop suit canine-focus antibodi target atop dermat particular
compani portfolio potenti industry-lead companion anim biolog target larg market
opportun expect kindr antibodi develop program largest long-term valu
driver first product expect market kindr pursu multi-
prong approach toward atop dermat intend advanc fulli canon
antibodi fulli canon antibodi canin sink molecul pilot
efficaci studi data pilot studi determin kindr proce atop
dermat program expect pilot data atop dermat program end
potenti begin pivot trial
given size atop dermat market consid second-most-common
allerg skin diseas dog kindr expect pivot studi commenc fairli
non-regen anemia market modelnumb cat number cat ckd percentag cat treat ckd treat ckd epocat annual revenu per patient target annul market market share treat epocat year end decemb juli
zoeti current domin canin atop dermat market apoquel cytopoint zoeti
expect two product gener peak sale although compani could
exceed forecast given report combin revenu two product
accord american pet product associ appa dog
dog affect atop dermat popul dog increas
continu grow singl suffici treatment cure canin
atop dermat heterogen diseas howev mab shown success
manag diseas easi administr long-last effect
current treatment atop dermat includ oral topic glucocorticoid jak inhibitor
cyclosporin antihistamin allergen specif immunotherapi monoclon antibodi ztss
apoquel cytopoint
expect approv first kindr atop dermat antibodi model kindr
gener sale within five year launch base annual cost around
launch estim treatment dog cytopoint current cost
owner per inject depend size dog effect last
four-to-eight week translat inject per year cytopoint
kindr develop treatment equin gastric ulcer common condit found
hors kindr complet pilot effect studi studi
random single-blind placebo-control dose-rang studi enrol hors hors
three group differ dose dose schedul hors placebo
group object determin effect dose treatment gastric
ulcer hors week gastric ulcer resolut gastric ulcer rate three kind-
group statist significantli higher placebo group p-valu
expect read-out pivot result potenti approv
model revenu begin expect revenu
immedi accret kindr oper incom given compani alreadi equin
sale forc place promot zimeta kindr yet disclos rout administr
activ ingredi
antibodi market modelnumb dog own number dog atop dermat annual per patient target market annual market share dog atop dermat antibodi cantor fitzgerald research compani reportsfisc year end decemb juli
ulcer common medic condit hors foal foal one-third adult
hors confin stall affect mild ulcer addit high-valu hors higher
preval rate show hors racehors develop moderate-to-sever
ulcer common syndrom develop non-glandular region hors stomach
caus diarrhea poor appetit poor bodi condit weight loss excess time spent lay
decreas perform behavior chang sever factor lead symptom equin
gastric ulcer includ hors feed schedul stress level strenuou exercis
way prevent treat condit without use medic howev symptom becom
sever medic need
equin gastric ulcer treat antacid requir administr time day
lead product use treat ulcer merial gastrogard omeprazol ulcergard
omeprazol gastrogard use treat exist equin stomach ulcer wherea ulcergard use
prevent estim product combin gener annual revenu
merial kindr success bring market believ could largest
product compani equin portfolio
equin gastric ulcer market modelnumb hors number hors equin ulcer percentag hors treat equin hors treat equin ulcer annual revenu per patient target market annual market share hors treat gastric year end decemb competitor industri major product
accord american pet product associ appa overal spend pet
market expect veterinari care suppli over-the-counter
medic spend shown compound-annual-growth-rate last year
exhibit spend veterinari suppli over-the-counter medic sinc
expect anim health spend remain robust expect larger compani industri
grow pet ownership across gener remain strong gener among most-
numer owner dog cat hors babi boomer largest segment pet
owner shift gener pet health insur penetr level remain low
dog cat cover although may continu increas gener
appear like obtain pet health insur older pet owner increas pet-own
insur posit anim health industri owner may will spend
higher-pr drug insur said anim drug price increas rapidli cheaper
effect altern becom avail insur may eventu push pet owner toward cheaper
altern although expect happen short-to-medium term addit
anoth posit kindr accord appa hors owner highest averag
household incom follow bird fish dog small anim owner averag dog visit
veterinarian time per year compar time per year cat
exhibit pet ownership gener
spend across categori med veterinari live anim salesoth supplies/otc medic spend med veterinari juli
importantli appa nation pet owner survey ask pet owner
economi influenc amount spent pet respond note spend
pet influenc economi accord american pet product associ
cat dog total although dog owner
tend spend margin pet year
given continu tailwind anim health industri expect kindr well
competitor continu deliv solid growth larg anim health compani may compet
kindr includ merck anim health anim health divis merck co inc
cover elanco anim health divis eli lilli compani ow cover
louis chen bayer anim health anim health divis bayer ag bayn cover
boehring ingelheim anim health anim health divis boehring ingelheim privat
gmbh zoeti inc addit kindr also compet smaller anim health
compani europ virbac group anim health dechra pharmaceut
plc cover well inc cover
kindr current sever provision non-provision patent applic issu
patent kindr product candid base gener human drug
littl composition-of-matt patent protect avail activ pharmaceut ingredi
api product candid howev kindr intend pursu intellectu properti protect
current compound futur compound proprietari technolog enhanc
formul seen mirataz kindr file composition-of-matt patent mani
biolog
founder chief
chief oper
richard chin harvard-train physician former rhode scholar work
drug approv ind drug dr chin develop includ lucenti xolair
tysabri rituxan immun diseas current aggreg sale well per year
previous dr chin head clinic research biotherapeut genentech
oversaw genentech drug develop program except oncolog product senior vice-president
global develop ceo oxigen nasdaq-list biotechnolog compani ceo
oneworld health gate foundation-fund nonprofit develop drug impoverish patient
develop countri dr chin name businessweek one youngest public-
compani ceo unit state author sever major textbook clinic develop
teach drug develop ucsf
denis bever expert clinic oper medic affair scientif commun ms
bever year pharmaceut research experi manag dozen
product develop program phase phase iv previous work
pharmaceut scripp clinic research foundat quintil skyepharma recent
presid found sd scientif full-servic medic affair
dr zhan highli regard protein biochemist biophysicist year drug discoveri
experi biotechnolog industri join kindredbio februari lead biolog
research recent dr zhan serv execut member aragen bioscienc led
protein scienc group prior dr zhan establish led protein biochemistri group
proteom team work led drug candid prior dr zhan
group leader protein chemistri axi biopharmaceut celera manag
ferment group protein biochemistri group dr zhan complet post-doctor train
dr john collier lab harvard medic school appli in-depth biophys elucid
dynam protein structur chang solut membran receiv ph
univers washington discov novel chemic signal molecul involv
wendi wee financi execut year public compani experi
biotechnolog high technolog industri ms wee serv variou
posit telik biotechnolog compani focus oncolog posit includ vice
presid financ princip financi account offic control prior telik
senior director financ control connet inc biotechnolog compani
focus dermatolog diseas held variou manag posit silicon
graphic inc mip comput system unisi corpor
arriv price target
use blend dcf multipl ev/ebitda analysi get price target
dcf analysi result share price use wacc exit
multipl forward ebit premium specialti pharma group peer trade
averag forward ev/ebit believ kindr deserv premium valuat
specialti pharma peer given compani robust pipelin durabl natur anim health
revenu refer trade consensu ev/ebitda
multipl ev/ebitda analysi arriv share price appli
forward ev/ebitda multipl estim kindr ebitda
subtract debt ev add back cash arriv equiti valu divid equiti
valu share count get price per share discount back eight year arriv
price per share forward ev/ebitda multipl appli compar favor
forward ev/ebitda multipl peer trade averag forward ev/ebitda
assumpt except per share rate end decemb taxes- depreci less capit chang work free free termin dilut share cantor fitzgerald research compani report juli
bull bear base case analysi
also use blend dcf multipl ev/ebitda analysi arriv bull
bear case scenario base analysi estim likelihood stock worth
next month
use follow compani kindr peer neutral cover louis chen
overweight chen ow akao nc nc cover tanner
cover tanner mdco nc ow chen chen ow chen opnt
nc scyx nc ow chen teva chen ttph nc ow cover
tanner vrx ow chen xene nc ow chen
exhibit kindr bull bear base case scenario analysi
kindredsourc cantor fitzgerald research compani casemirataz uptak street forecastspipelin advanc includ biologicsaddit busi scenario casemirataz uptak linepipelin advanc includ biologicsno addit busi scenario casemirataz revenu current forecastno biolog pipelin advancementsno addit busi scenario juli
risk valuat
kindr current one approv product mirataz sale mirataz
expect may hamper compani abil meet expect financ remain
kindr depend substanti success pipelin may receiv regulatori
approv unit state europ
posit studi trial result obtain to-dat may disput fda review guarante
regulatori approv may obtain futur clinic trial
kindr need addit capit pursu commerci product candid
uptak mirataz remain pipelin forecast
lack new product launch and/or failur exist product gain market share could affect
compani result street posit expect kindr new launch compani
perform line better expect could downsid risk number
macro factor could advers affect sale earn
brand gener compound product competit key drug could headwind kindr
sale given limit number product pipelin unforeseen competit one key
product could meaning affect compani abil meet expect rais capit
need kindr pipelin product compani abl bring
market allevi risk
million compound-annual-growth-rate year end decemb revenu oper share chang yoytot cantor fitzgerald research compani report exhibit margin analysi
revenu cantor fitzgerald research compani report exhibit sale analysi
million year end decemb fever equin gastric equin metabol antibodi sick antibodi ib product agreement chang fever equin gastric equin metabol antibodi sick foalsnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmanti-tnf antibodi ib dogsnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmothernmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmtot product agreement revenuenmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmcontract revenuenmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmothernmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmtot cantor fitzgerald research compani report exhibit annual sale analysi
 fever equin gastric equin metabol antibodi sick antibodi ib product agreement cantor fitzgerald research compani reportsyear end decemb exhibit statement analysi
million year end decemb flow provid oper activ net depreci net chang work net cash provid oper flow invest activitiespurchas pp capit net proce sale acquisit net cash acquired- other- net cash use invest flow financ activ repay issuanc long term debt- proce issuanc other- net cash use provid financ net decreas increas cash equival begin equival end sourc cantor fitzgerald research compani report exhibit balanc sheet analysi
million year end decemb account receiv less allow doubt accounts- inventories- current total current plant properti identifi intangibles- goodwill- total total liabil sharehold equityaccount payabl accru total current long term debt total sharehold total stockhold non-controlling interest- total liabil stockhold sourc cantor fitzgerald research compani report juli
target price buy top shareholdersexhibit cantor estim versu consensusexhibit sell side rate price targetsexhibit one year share price share west asset manag richard stanley co invest fund advisor vanguard group fund american investor co inc invest view asset manag fund manag fargo clear servic trust invest capit york state common retir etf solut capit manag invest manag riley capit manag associ financi servic inc invest denis invest manag clark lunn invest manag juli
kindr commercial-stag biopharmaceut compani focus develop commerci novel product aim toward pet
kindr strategi identifi compound target alreadi demonstr safeti efficaci human develop
therapeut base valid compound target pet primarili dog cat hors use approach kindr
expect higher approv success rate shorter develop timelin compar pursu new non-valid compound target
kindr pipelin consist small molecul biolog rang indic dog cat hors near-term focu
equin small molecul product canin felin biolog product
compani nyse overweight
price close jul
